Dual Erb B Inhibition in Oesophago-gastric Cancer

• Research type

  Research Study

• Full title

  A Phase I dose-escalating and safety study of AZD8931 in combination with Oxaliplatin and Capecitabine chemotherapy in patients with Oesophago-gastric adenocarcinoma

• IRAS ID

  98024

• Contact name

  Anne Thomas

• Eudract number

  2011-003169-13

• ISRCTN Number

  N/A

• Clinicaltrials.gov Identifier

  N/A

• Research summary

  AZD8931 blocks a growth pathway that is important in some cancers. In the escalation phase this trial will define the dose of AZD8931 that can safely be given with standard chemotherapy for oesophageal (gullet) cancer. We will then (in the expansion phase) compare the side effects of chemotherapy alone with those of AZD8931 with chemotherapy in 30 people with operable gullet cancer. This will to decide how to run future studies of AZD8931 with chemotherapy. This trial is supported by the Experimental Cancer Medicine Centres - Astrazeneca Combinations Alliance, and by the New Agents committee of Cancer Research UK. It is being run at hospitals in Oxford, Leicester and Belfast. Patients who go on the trial will need to undergo extra tests to check it is safe for them to take part, and to monitor them whilst on treatment.

• REC name

  South Central - Oxford C Research Ethics Committee

• REC reference

  12/SC/0090

• Date of REC Opinion

  18 Apr 2012

• REC opinion

  Further Information Favourable Opinion